Novel HCV Drug Can Double Response Rate (CME/CE)
(MedPage Today) -- An investigational protease inhibitor aimed at blocking hepatitis C replication can double the response rate compared with standard care, researchers said.
Comments are closed.
All rights reserved. © UK. Site Map | Contact us | About us | Contributors | Supporters | Terms & Conditions
This site complies with the HONcode standard for trustworthy health information: verify here.